TICKERNERD
Menu
BEAMBEAMHealthcare · Biotechnology

BEAM Stock Forecast: Beam Therapeutics, Inc. Price Predictions for 2026-2027

Last close, 4 Sept 2026
$30
+0.68% on the day

The 15 Wall Street analysts covering Beam Therapeutics, Inc. hold a median 12-month price target of $45 — +51.7% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 48 of 100 as at 5 Sept 2026 — in the lower half.

Market cap
$3.1B
Ticker Nerd rank
48 / 100
Median analyst target
$45
Analysts covering
15
Revenue$490K−94.2% y/y
Operating income−$126.6M
Net income−$122.7M
Free cash flow−$68.5M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
+1.2%
1M
+4.6%
YTD
+7.0%
1Y
+60.0%
From 52W high
−21.8%
From 52W low
+60.0%
$19
$38
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

BEAM stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Beam Therapeutics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 5 Sept 2026
48 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Growth
98
Quality
72
Momentum
64
Value
58
Revisions
52
Size
30
Accruals
29
Volatility
28
Issuance
17

Growth (98): Sales and profits are climbing, and climbing faster than before.

Issuance (17): The company has been issuing shares or taking on financing, diluting existing holders.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

BEAM stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on BEAM, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$20$40$60$80Oct 25Jan 26Apr 26Jul 26BEAMHigh $80Median $45Low $26

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says15 analysts
13 Buy2 Hold0 Sell
Low $26Median $45High $80

The green dot is the last close — the median target sits +51.7% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
25 Aug 2026HC Wainwright & Co.ReiteratesBuy$80
8 July 2026B of A SecuritiesReiteratesBuy—
8 July 2026B of A SecuritiesReiteratesBuy$47
7 July 2026HC Wainwright & Co.ReiteratesBuy—
7 July 2026HC Wainwright & Co.ReiteratesBuy$80
13 May 2026BernsteinMaintainsOutperform—
26 Mar 2026CitigroupMaintainsBuy—
25 Feb 2026RBC CapitalMaintainsSector Perform—
25 Feb 2026WedbushMaintainsOutperform—
20 Feb 2026Canaccord GenuityInitiatesBuy—
21 Jan 2026BernsteinMaintainsOutperform—
7 Jan 2026UBSInitiatesNeutral—
24 Nov 2025Evercore ISI GroupInitiatesOutperform—
10 Oct 2025HC Wainwright & Co.ReiteratesBuy—
9 Oct 2025JP MorganMaintainsOverweight—
15 Sept 2025HC Wainwright & Co.ReiteratesBuy—
6 Aug 2025BarclaysMaintainsEqual-Weight—
7 May 2025BarclaysMaintainsEqual-Weight—
7 May 2025GuggenheimMaintainsBuy—
7 May 2025Wells FargoMaintainsOverweight—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. BEAM appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Performance

BEAM vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 4 Sept 2026, Beam Therapeutics, Inc. returned +60.0% against +20.0% for the S&P 500, dividends included.

BEAM vs S&P 500, last 12 monthsTotal return, rebased to 100
100120140160180200Oct 25Jan 26Apr 26Jul 26BEAMS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

BEAM analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
4
Analysts cutting
5
Fundamentals

Beam Therapeutics, Inc. (BEAM) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−36.6×

Cheaper than 98% of US stocks

Price / sales
19.6×

Cheaper than 9% of US stocks

Price / book
2.8×

Cheaper than 36% of US stocks

EV / EBITDA
−5.8×

Cheaper than 79% of US stocks

Growth & margins
Revenue growth (YoY)
−94.2%

Higher than 2% of US stocks

Earnings growth (YoY)
−94.2%

Higher than 3% of US stocks

Gross margin
—
Operating margin
−25827.1%

Higher than 1% of US stocks

Net margin
−55.4%

Higher than 10% of US stocks

Returns & dividend
Return on equity
−8.2%

Higher than 37% of US stocks

Return on assets
−17.0%

Higher than 21% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Beam Therapeutics, Inc. (BEAM) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Beam Therapeutics, Inc. has a market value of $3.1B and an enterprise value of $2.1B.

  • Revenue in the twelve months to 30 June 2026: $156.0M. The latest quarter shrank 94.2% year on year.

  • Net income over the same four quarters: −$85.4M, a −54.7% net margin.

  • Diluted earnings per share, trailing twelve months: $−0.86.

  • Free cash flow in the twelve months to 30 June 2026: −$372.8M.

  • Shares outstanding: 103.3M.

  • Trailing P/E: −36.6×; forward P/E: −6.3× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Beam Therapeutics, Inc. employs 540 people — $289K of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 8 Sept 2026

Data provided by Twelve Data

Peers

BEAM vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
BEAMBeam Therapeutics, Inc.$3.1B
48
QUREUniQure NV$3.0B
54
CLDXCelldex Therapeutics, Inc.$3.1B
30
ARQTArcutis Biotherapeutics, Inc.$3.0B
88
IRONDisc Medicine, Inc.$3.0B
37
IMNMImmunome, Inc.$3.0B
33
MBXMBX Biosciences, Inc.$2.9B
35

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Beam Therapeutics, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest BEAM news & analysis

Beam Therapeutics Appoints Eric Foster as Chief Commercial Officer

GlobeNewsWire · 1 Sept 2026positive

Beam Therapeutics announced the appointment of Eric Foster as chief commercial officer. Foster will lead the company's commercial organization and strategy as Beam advances multiple product candidates across its hematology and genetic disease franchises toward potential launches.

Why it matters — The appointment brings dedicated commercial leadership to support Beam's pipeline as it prepares for potential product launches.

Beam Therapeutics to Participate in Upcoming September 2026 Investor Conferences

GlobeNewsWire · 31 Aug 2026neutral

Beam Therapeutics announced that its management will participate in fireside chats at upcoming investor conferences in September 2026. The company develops precision genetic medicines through base editing.

Why it matters — BEAM watchers would care because these conference appearances give investors opportunities to hear management discuss the company's base-editing programs.

4 Gene-Editing Biotech Stocks Worth Watching for Long-Term Gains

Zacks Investment Research · 24 Aug 2026positive

Zacks Investment Research highlighted four gene-editing biotech stocks, including Beam Therapeutics (BEAM), as worth watching for long-term gains. The article notes that these companies span commercial validation, late-stage catalysts, and promising early-stage gene-editing programs.

Why it matters — BEAM watchers may gain context on how Beam's early-stage gene-editing programs compare with peers across commercial and late-stage development stages.

BEAM's Q2 Loss Wider Than Expected, Revenues Fall Y/Y, Pipeline in Focus

Zacks Investment Research · 5 Aug 2026negative

Beam Therapeutics reported a wider-than-expected Q2 loss and revenues that fell short of estimates, while continuing to advance its genome-editing pipeline toward key clinical milestones.

Why it matters — The wider loss and revenue miss could raise concerns about the company's financial performance even as its pipeline progress remains a focus for investors.

Beam Therapeutics Inc. (BEAM) Reports Q2 Loss, Lags Revenue Estimates

Zacks Investment Research · 4 Aug 2026negative

Beam Therapeutics reported a second-quarter loss of $1.18 per share, wider than the Zacks Consensus Estimate of a $1 per-share loss and a year-ago loss of $1 per share. The report also lagged revenue estimates according to the headline.

Why it matters — The quarterly loss came in above the consensus estimate, which matters to BEAM watchers as a miss on expectations.

FAQ

Frequently asked questions about BEAM stock

What is the BEAM stock price forecast for 2026-2027?

The 15 Wall Street analysts covering Beam Therapeutics, Inc. have a median 12-month price target of $45, with estimates ranging from $26 to $80. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is BEAM stock a buy right now?

Of the 15 analysts covering Beam Therapeutics, Inc., 13 rate it a Buy, 2 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Beam Therapeutics, Inc. 48 out of 100 across roughly 4,600 US stocks as at 5 Sept 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank BEAM?

As at 5 Sept 2026, Beam Therapeutics, Inc. ranks 48 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Growth (98 of 100).

Will BEAM stock go up?

No one can know that. What the data says: the median 12-month target from 15 analysts implies +51.7% from the last close, and Ticker Nerd's factor model ranks Beam Therapeutics, Inc. 48 out of 100 as at 5 Sept 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the BEAM stock forecast for 2030?

No analyst covering Beam Therapeutics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for BEAM are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $26 to $80 over the next 12 months.

How has BEAM stock performed over the past year?

Beam Therapeutics, Inc. returned +60.0% over the 12 months to 4 Sept 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Beam Therapeutics, Inc. do?

Beam Therapeutics Inc. is a biotechnology company focused on developing precision genetic medicines using its proprietary base editing platform.

What is the latest news on BEAM?

The most recent item we track (GlobeNewsWire, 1 Sept 2026): "Beam Therapeutics Appoints Eric Foster as Chief Commercial Officer". Beam Therapeutics announced the appointment of Eric Foster as chief commercial officer. Foster will lead the company's commercial organization and strategy as Beam advances multiple product candidates across its hematology and genetic disease franchises toward potential launches.

Company

About Beam Therapeutics, Inc.

Beam Therapeutics Inc. is a biotechnology company focused on developing precision genetic medicines using its proprietary base editing platform. The company works on therapies designed to make targeted, single-letter changes in DNA without creating double-strand breaks, supporting programs aimed at serious genetic and hematologic diseases. Its current pipeline includes research and clinical candidates across areas such as blood disorders, liver diseases, and other rare conditions. Beam Therapeutics also maintains integrated capabilities in gene editing, delivery, and internal manufacturing to support the development of its therapeutic candidates. Based in Cambridge, Massachusetts, Beam Therapeutics plays a role in the advanced genomics and gene-editing market, where precision medicine approaches are being applied to address diseases with limited treatment options.

CEO Mr. John M. Evans M.B.A. · 540 employees · United States · https://beamtx.com